Transporters Involved in Metformin Pharmacokinetics and Treatment Response

Journal of Pharmaceutical Sciences

Volumn 106, Issue 9, 2017, Pages 2245-2250

  Liang, Xiaomin ^a   Giacomini, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADME; clinical pharmacokinetics; drug interactions; membrane transporter; organic cation transporters; pharmacogenomics; pharmacokinetics pharmacodynamics

Indexed keywords

CARNITINE TRANSPORTER 1; CIMETIDINE; FAMOTIDINE; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PAROXETINE; PYRIMETHAMINE; SEROTONIN TRANSPORTER;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SHORT SURVEY; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; ANIMAL; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE TRANSPORTER TYPE 2; HUMANS; METFORMIN; POLYMORPHISM, GENETIC;

EID: 85023615225     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2017.04.078     Document Type: Short Survey

References (66)

1. Pernicova, I., Korbonits, M., Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10:3 (2014), 143–156.
2. Rojas, L.B.A., Gomes, M.B., Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr, 5(1), 2013, 6.
3. Cicero, A.F., Tartagni, E., Ertek, S., Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci 8 (2012), 907–917.
4. Kita, Y., Takamura, T., Misu, H., et al. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One, 7(9), 2012, e43056.
5. Nath, N., Khan, M., Paintlia, M.K., Singh, I., Hoda, M.N., Giri, S., Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 182:12 (2009), 8005–8014.
6. Graham, G.G., Punt, J., Arora, M., et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:2 (2011), 81–98.
7. Wu, C.-Y., Benet, L.Z., Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:1 (2005), 11–23.
8. Tucker, G.T., Casey, C., Phillips, P.J., Connor, H., Ward, J.D., Woods, H.F., Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:2 (1981), 235–246.
9. Scheen, A.J., Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:5 (1996), 359–371.
10. Pentikäinen, P.J., Neuvonen, P.J., Penttilä, A., Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 16:3 (1979), 195–202.
11. Jonker, J.W., Wagenaar, E., Mol, C.A., et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 21:16 (2001), 5471–5477.
12. Shu, Y., Leabman, M.K., Feng, B., et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A 100:10 (2003), 5902–5907.
13. Nakamichi, N., Shima, H., Asano, S., et al. Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. J Pharm Sci 102:9 (2013), 3407–3417.
14. Zhou, M., Xia, L., Wang, J., Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35:10 (2007), 1956–1962.
15. Chen, E.C., Liang, X., Yee, S.W., et al. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. Mol Pharmacol 88:1 (2015), 75–83.
16. Masuda, S., Terada, T., Yonezawa, A., et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:8 (2006), 2127–2135.
17. Liang, X., Chien, H.-C., Yee, S.W., et al. Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3). Mol Pharm 12:12 (2015), 4301–4310.
18. Kimura, N., Masuda, S., Tanihara, Y., et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:5 (2005), 379–386.
19. Li, S., Chen, Y., Zhang, S., More, S.S., Huang, X., Giacomini, K.M., Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm Res 28:3 (2011), 610–625.
20. Choi, M.-K., Jin, Q.-R., Jin, H.-E., et al. Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos 28:9 (2007), 501–510.
21. Chen, Y., Teranishi, K., Li, S., et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharm J 9:2 (2009), 127–136.
22. Han, T., Proctor, W.R., Costales, C.L., Cai, H., Everett, R.S., Thakker, D.R., Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers. J Pharmacol Exp Ther 352:3 (2015), 519–528.
23. Kajbaf, F., De Broe, M.E., Lalau, J.D., Therapeutic concentrations of metformin: a systematic review. Clin Pharmacokinet 55 (2016), 439–459.
24. Gong, L., Goswami, S., Giacomini, K.M., Altman, R.B., Klein, T.E., Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22:11 (2012), 820–827.
25. Zhou, K., Yee, S.W., Seiser, E.L., et al. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48 (2016), 1055–1059.
26. Hume, W.E., Shingaki, T., Takashima, T., et al. The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. Bioorg Med Chem 21:24 (2013), 7584–7590.
27. Shingaki, T., Hume, W.E., Takashima, T., et al. Quantitative evaluation of mMate1 function based on minimally invasive measurement of tissue concentration using PET with [(11)C]metformin in mouse. Pharm Res 32:8 (2015), 2538–2547.
28. Kusuhara, H., Ito, S., Kumagai, Y., et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:6 (2011), 837–844.
29. Ito, S., Kusuhara, H., Yokochi, M., et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340:2 (2012), 393–403.
30. Dujic, T., Zhou, K., Yee, S.W., et al. Variants in pharmacokinetic transporters and glycemic response to metformin: a metgen meta-analysis. Clin Pharmacol Ther, 2016.
31. Sambol, N.C., Chiang, J., Lin, E.T., et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 35:11 (1995), 1094–1102.
32. Klepser, T.B., Kelly, M.W., Metformin hydrochloride: an antihyperglycemic agent. Am J Health Syst Pharm 54:8 (1997), 893–903.
33. Proctor, W.R., Bourdet, D.L., Thakker, D.R., Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 36:8 (2008), 1650–1658.
34. Engel, K., Zhou, M., Wang, J., Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279:48 (2004), 50042–50049.
35. Engel, K., Wang, J., Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68 (2005), 1397–1407.
36. Xia, L., Engel, K., Zhou, M., Wang, J., Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. Am J Physiol Renal Physiol 292:2 (2007), F682–F690.
37. Estudante, M., Morais, J.G., Soveral, G., Benet, L.Z., Advanced drug delivery reviews. Adv Drug Deliv Rev 65:10 (2013), 1340–1356.
38. Müller, J., Lips, K.S., Metzner, L., Neubert, R., Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70 (2005), 1851–1860.
39. Owens, M.J., Morgan, W.N., Plott, S.J., Nemeroff, C.B., Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:3 (1997), 1305–1322.
40. Sirtori, C.R., Franceschini, G., Galli-Kienle, M., et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 24:6 (1978), 683–693.
41. Shu, Y., Brown, C., Castro, R.A., et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:2 (2008), 273–280.
42. Kekuda, R., Prasad, P.D., Wu, X., et al. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 273:26 (1998), 15971–15979.
43. Bleasby, K., Castle, J.C., Roberts, C.J., et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:10-11 (2006), 963–988.
44. Lee, N., Duan, H., Hebert, M.F., Liang, C.J., Rice, K.M., Wang, J., Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. J Biol Chem 289:39 (2014), 27055–27064.
45. Gormsen, L.C., Sundelin, E.I., Jensen, J.B., et al. In vivo imaging of human 11C-metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses. J Nucl Med 57:12 (2016), 1920–1926.
46. Jonker, J.W., Wagenaar, E., Van Eijl, S., Schinkel, A.H., Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23:21 (2003), 7902–7908.
47. Matsushima, S., Maeda, K., Inoue, K., et al. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:3 (2009), 555–559.
48. Tsuda, M., Terada, T., Mizuno, T., Katsura, T., Shimakura, J., Inui, K.-I., Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:6 (2009), 1280–1286.
49. Motohashi, H., Inui, K.-I., Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J 15:2 (2013), 581–588.
50. Lepist, E.-I., Ray, A.S., Renal transporter-mediated drug-drug interactions: are they clinically relevant?. J Clin Pharmacol 56:Suppl 7 (2016), S73–S81.
51. Ito, S., Kusuhara, H., Kuroiwa, Y., et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333:1 (2010), 341–350.
52. Yonezawa, A., Inui, K.-I., Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol 164:7 (2011), 1817–1825.
53. Hibma, J.E., Zur, A.A., Castro, R.A., et al. The effect of famotidine, a mate1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacokinet 55 (2015), 711–721.
54. Stocker, S.L., Morrissey, K.M., Yee, S.W., et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 93:2 (2013), 186–194.
55. Chen, Y., Li, S., Brown, C., et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19:7 (2009), 497–504.
56. Shikata, E., Yamamoto, R., Takane, H., et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 52:2 (2007), 117–122.
57. Higgins, J.W., Bedwell, D.W., Zamek-Gliszczynski, M.J., Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos 40:6 (2012), 1170–1177.
58. Toyama, K., Yonezawa, A., Masuda, S., et al. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. Br J Pharmacol 166:3 (2012), 1183–1191.
59. Shu, Y., Sheardown, S.A., Brown, C., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:5 (2007), 1422–1431.
60. Wang, D.-S., Jonker, J.W., Kato, Y., Kusuhara, H., Schinkel, A.H., Sugiyama, Y., Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:2 (2002), 510–515.
61. Jensen, J.B., Sundelin, E.I., Jakobsen, S., et al. [11C]-Labeled metformin distribution in the liver and small intestine using dynamic positron emission tomography in mice demonstrates tissue-specific transporter dependency. Diabetes 65:6 (2016), 1724–1730.
62. Shu, Y., Sheardown, S.A., Brown, C., et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 117:2 (2007), 1422–1431.
63. Becker, M.L., Visser, L.E., van Schaik, R.H.N., Hofman, A., Uitterlinden, A.G., Stricker, B.H.C., Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58:3 (2009), 745–749.
64. Choi, J.H., Yee, S.W., Ramirez, A.H., et al. A common 5′-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 90:5 (2011), 674–684.
65. Zhou, K., Donnelly, L.A., Kimber, C.H., et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58:6 (2009), 1434–1439.
66. Burcelin, R., Dolci, W., Thorens, B., Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. Diabetes 49:10 (2000), 1643–1648.